医疗器械公司Glaukos（GKOS）今日盘后股价大跌6.63%，尽管公司发布的第一季度财报显示业绩超出市场预期。这一意外走势引发了投资者对公司长期盈利能力的担忧。
根据Glaukos公布的财报，截至3月31日的第一季度，公司调整后每股亏损为0.22美元，优于分析师预期的0.35美元亏损。营收同比增长24.6%至1.0666亿美元，同样超过分析师预期的1.025亿美元。然而，尽管业绩超预期，公司仍然录得1815万美元的净亏损。
值得注意的是，Glaukos股价在过去一个季度已下跌4.7%，今年迄今累计跌幅高达37.4%。这表明投资者对公司的长期发展前景持谨慎态度。尽管分析师对该股票的平均评级为"买入"，且华尔街给出的12个月目标价中位数为160.00美元，但持续的亏损状况似乎仍然令市场感到不安。这可能是导致公司股价在盘后交易中大幅下跌的主要原因。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.